Oncology
NCCN Awarded $2 Million in Research Funding from Taiho Oncology to Study Trifluridine and Tipiracil in Various Cancers
National Comprehensive Cancer Network
PR-M10-18-NI-077Oct 23, 2018
Oncology
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Taiho Oncology, Inc.
PR-M05-18-NI-045May 11, 2018
Symposium
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium
Taiho Oncology, Inc.
PR-M01-18-NI-080Jan 25, 2018